A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy

Trial Profile

A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs OCV C01 (Primary)
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPETE-PC; R000008586
  • Sponsors OncoTherapy Science
  • Most Recent Events

    • 20 Dec 2013 Primary endpoint 'Overall-survival' has not been met.
    • 20 Dec 2013 Status changed from recruiting to discontinued, as reported in an OncoTherapy Science media release.
    • 19 Dec 2013 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top